WOMENS ISCHEMIC SYNDROME EVALUATION

UAB是参与NHLBI赞助的妇女缺血综合征评估（WISE）的四个临床站点之一。 WISE是一项为期3年的研究，旨在开发更好的工具来检测女性心肌缺血。 其基本前提是，所有目前可用的临床试验检测女性心肌缺血的可靠性低于男性。在UAB，我们计划评估的敏感性和特异性检测缺血与休息/潘生丁心肌灌注，同时评估钆-MRI和混合铊/sestamibi造影。 其他机构将测试不同的方式，包括磁共振冠状动脉造影，多巴酚丁胺磁共振标记，多巴酚丁胺超声心动图，PET和心肌造影超声心动图。UAB的一个由234名妇女组成的研究组，30%是少数民族，将与其他参与WISE的中心收集某些共同的数据，包括详细的心理社会/症状问卷、女性激素评估、动态心电图和冠状动脉造影。 完成诊断检测后，在研究期间每6个月进行一次电话联系，以评估生命状态和发病率。

UAB is one of four clinical sites participating in the Women's Ischemic Syndrome Evaluation (WISE), sponsored by the NHLBI. WISE is a 3 year study which seeks to develop better tools for detecting myocardial ischemia in women. The underlying premise is that all currently available clinical tests have a lower reliability for detecting myocardial ischemia in women than in men. At UAB, we plan to evaluate the sensitivity and specificity of detecting ischemia with rest/persantine myocardial perfusion as assessed simultaneously by gadolinium-MRI and by hybrid thallium/sestamibi scintigraphy. Other institutions will be testing different modalities including MRI coronary arteriography, dobutamine MRI tagging, dobutamine echocardiography, PET, and myocardial contrast echocardiography. A study group of 234 women at UAB, 30% minority, will have certain common data collected with the other participating WISE centers, including a detailed psychosocial/symptoms questionnaire, female hormone assessment, ambulatory ECG and coronary arteriography. Following completion of diagnostic testing, telephone contact will be made at 6 month intervals for the duration of the study to assess vital status and morbidity.